Caplight Directory>Companies>Excalipoint Therapeutics-preview>Excalipoint


Excalipoint Therapeutics

Excalipoint Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttps://excalipoint.com/

Last Round

Seed

Mar 18, 2026

Total Funding Raised

$109.7M

Company Overview

Excalipoint Therapeutics is a clinical-stage biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

T-cell engagerTCE therapymulti-specific antibodiestri-specific antibodiesimmuno-oncologysolid tumor therapiesantibody engineeringbiologics platformtumor microenvironmentTMEconditional activationantibody maskingsmall cell lung cancerSCLCDLL3 targetbiotech out-licensingautoimmune disease treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Excalipoint Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Excalipoint Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
SeedMar 18, 2026
SeedAug 1, 2025
View all Funding Rounds

Excalipoint Therapeutics Investors

Notable investors and investment history

InvestorRounds
Centurium CapitalSeed
Co-Win VenturesSeed
YuanBio Venture CapitalSeed
Eisai InnovationSeed
Hony CapitalSeed
5Y CapitalSeed
MPCiSeed
View all Investors

Excalipoint Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Excalipoint Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Excalipoint Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2025
Last FundingMar 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.